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OBJECTIVES The study compared the safety and efficacy of ticlopidine with clopidogrel in patients
receiving coronary stents.
BACKGROUND Stent thrombosis is reduced when ticlopidine is administered with aspirin. Clopidogrel is
similar to ticlopidine in chemical structure and function but has fewer side effects; few data
are available about its use in stent patients.
METHODS We compared 30-day event rates in 500 consecutive coronary stent patients treated with
aspirin and clopidogrel (300 mg loading dose immediately prior to stent placement, and
75 mg/day for 14 days) to 827 consecutive stent patients treated with aspirin and ticlopidine
(500 mg loading dose and 250 mg twice daily for 14 days).
RESULTS Patients treated with clopidogrel had more adverse clinical characteristics including older age,
more severe angina, and more frequent infarction within the prior 24 h. Nonetheless,
mortality was 0.4% in clopidogrel patients versus 1.1% in ticlopidine patients; nonfatal
myocardial infarction occurred in 0% versus 0.5%, stent thrombosis in 0.2% versus 0.7%,
bypass surgery or repeat angioplasty in 0.4% versus 0.5%, and any event occurred in 0.8%
versus 1.6% of patients, respectively (p 5 NS). Based on the observed 30-day event rate of
1.6% with ticlopidine, the statistical power of the study was 43% to detect an even rate of 0.5%
with clopidogrel, and 75% to detect an event rate with of 4% with clopidogrel, with a p value
of 0.05.
CONCLUSIONS These data indicate that clopidogrel can be safely substituted for ticlopidine in patients
receiving coronary stents. (J Am Coll Cardiol 1999;34:1891–4) © 1999 by the American
College of Cardiology
Improvements in coronary stent design, deployment tech-
niques, and antiplatelet therapy with ticlopidine and aspirin
have reduced the frequency of stent thrombosis to ,2%
(1–4). However, ticlopidine is associated with frequent side
effects including neutropenia and thrombotic thrombocyto-
penic purpura, which can be life-threatening (5,6).
See page 1895
Clopidogrel is a thienopyridine closely related to ticlopi-
dine in chemical structure and function but with fewer side
effects, and clopidogrel does not cause neutropenia or
thrombotic thrombocytopenic purpura (7,8). Clopidogrel
can also achieve platelet inhibition more rapidly (9). We
performed this prospective study to determine the risk of
stent thrombosis and other adverse events among patients
receiving intracoronary stents in whom clopidogrel was
administered with aspirin.
METHODS
Study population. Between March and August 1998, a
total of 500 consecutive patients underwent successful
intracoronary stent implantation at the Mayo Clinic with
clopidogrel and were compared with 827 patients who
received ticlopidine for 14 days between May 1996 and
October 1997 in a study of the use of ticlopidine for 14 days
(10). Reasons for exclusion were: warfarin requirement for
co-morbid conditions, research protocols requiring four
weeks of ticlopidine, contraindications to aspirin or thien-
opyridines, cardiogenic shock, or patient refusal of access to
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medical records for research. This study was approved by
the Mayo Clinic Institutional Review Board.
Primary end point. The primary end point was the occur-
rence of death, nonfatal myocardial infarction, stent throm-
bosis, and need for coronary bypass surgery or repeat
angioplasty within 30 days.
Stent procedure and medical therapy. Stents were im-
planted as previously described (10). All patients received
aspirin $325 mg. Clopidogrel was given as a 300-mg load
in the catheterization laboratory immediately before stent
implantation followed by 75 mg/day for 14 days. Ticlopi-
dine was given as a 500-mg load immediately before stent
implantation, 250 mg that evening, and 250 mg twice daily
for 14 days. During the procedure, weight-adjusted heparin
was given to achieve an activated clotting time of 300 s.
When abciximab was given at the discretion of the inter-
ventional cardiologist, lower doses of heparin were admin-
istered. Patients at increased risk of stent thrombosis (with
acute myocardial infarction or a suboptimal result) were
treated with subcutaneous enoxaparin 30 to 60 mg or
ardeparin 4,000 to 12,000 U twice daily for 10 to 14 days at
the discretion of their cardiologist.
Definitions. Lesions were prospectively characterized by
the modified American College of Cardiology/American
Heart Association classification scheme (11). Successful
stent placement was defined as stent delivery with achieve-
ment of a residual stenosis #20% and Thrombolysis in
Myocardial Infarction (TIMI) flow grade 3. Periprocedural
myocardial infarction was defined as prolonged chest pain or
a creatine kinase (CK) .23 normal or an elevated CK-MB
(creatine kinase–myocardial band) and new Q waves. Myo-
cardial infarction after discharge was diagnosed when two of
three criteria were met: prolonged chest pain, CK elevation
.23 normal or elevated CK-MB, or new Q waves or
significant ST-T changes. Stent thrombosis was diagnosed
if an angiogram revealed thrombus with diminished
(,TIMI flow grade 3), myocardial infarction occurred in
the distribution of the stented vessel, or after sudden death.
Follow-up. All patients were contacted by study coordina-
tors; the medical records of patients suffering events were
examined.
Statistics. Results are presented as mean 6 1 SD or a
percent of the total. Clinical and procedural characteristics
were compared using either Pearson’s chi-square or the
Student t test. The Fisher exact test was used to compare
event rates between the two cohorts.
RESULTS
Baseline characteristics. Patients treated with clopidogrel
had more adverse clinical characteristics than did
ticlopidine-treated patients. Stent placement was more fre-
quently elective in the clopidogrel cohort (Table 1).
Angiographic and procedural characteristics. Stents
placed in the two groups differed; newer stents had been
approved after the ticlopidine cohort had been treated. Low
molecular weight heparin was administered less frequently
to clopidogrel patients (Table 2).
Adverse events. The frequency of death, nonfatal infarc-
tion, stent thrombosis, and repeat angioplasty or bypass
surgery were slightly lower among patients treated with
clopidogrel, although the differences were not statistically
significant (Fig. 1). The cumulative occurrence of death,
myocardial infarction, stent thrombosis, and a repeat revas-
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
CK 5 creatine phosphokinase
CK-MB 5 creatine kinase–myocardial band
TIMI 5 Thrombolysis in Myocardial Infarction trial
Table 1. Baseline Characteristics
Ticlopidine
(N 5 827)
Clopidogrel
(N 5 500)
p
Value
Age, yrs (mean) 64.0 6 11 66.4 6 12.9 0.001
Male (%) 72 69 0.27
CHC 3–4 angina (%) 51 60 0.001
Diabetes mellitus (%) 18 21 0.001
Hypertension (%) 58 65 0.02
Hypercholesterolemia (%) 65 61 0.13
History of smoking (%) 64 62 0.53
Current smoker (%) 20 20 0.82
History of heart failure (%) 10 12 0.50
Prior bypass surgery (%) 20 21 0.48
Prior infarction (%) 49 54 0.09
#24 h (%) 10 15 0.02
Vessels diseased (%) 0.28
1 34 30
2 36 38
3 29 32
Left ventricular ejection
fraction (%)
63 6 15 57 6 15 0.001
(n 5 413) (n 5 205)
Treated vessel (%)
Left anterior descending 45 43 0.52
Circumflex 21 26 0.04
Right 34 36 0.39
Vein graft 9 10 0.74
Indication for stent
placement (%)
0.001
Elective 51 59
Dissection/acute closure 31 16
Suboptimal balloon
result
18 25
*Unknown in 5.2% and 6.2% of clopidogrel and ticlopidine patients, respectively, who
underwent angiography elsewhere.
CHC 5 Canadian Heart Classification.
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cularization procedure was 1.6% in the ticlopidine group
versus 0.8% in the clopidogrel group; the difference did not
reach statistical significance. In addition, neutropenia and
thrombotic thrombocytopenic purpura did not occur in any
patient.
DISCUSSION
The important finding in this study is that clopidogrel
administered for two weeks appears to be safe and effective
in patients undergoing intracoronary stent implantation.
Stent thrombosis and other adverse events occurred less
frequently in patients treated with clopidogrel than ticlopi-
dine despite more unfavorable clinical and anatomic char-
acteristics among clopidogrel patients, although the differ-
ences were not significant.
Ticlopidine. The clinical outcome of stent patients treated
with aspirin and ticlopidine is better than when aspirin and
warfarin (1–4) or aspirin alone (3,12,13) is administered.
Ticlopidine interferes with ADP-induced platelet-
fibrinogen binding by inhibiting up-regulation of glycopro-
tein IIb/IIIa receptors for the life of the platelet (6). Side
effects are common; the most serious are neutropenia and
thrombocytopenic purpura, which is often fatal (5,6). Full
platelet inhibition from ticlopidine requires $5 days of
treatment but can be shortened to 3 days with a 500-mg
loading dose (6). Larger loading doses frequently cause
nausea and are not generally used. The peak occurrence of
stent thrombosis in the first few days following stent
placement may be due to the slow onset of action of
ticlopidine (14–16).
Clopidogrel. Clopidogrel is closely related to ticlopidine in
chemical structure and function (7,8). The platelet inhibi-
tion achieved with clopidogrel 75 mg per day is equivalent
to that achieved with ticlopidine 250 mg twice daily (7).
The risk reduction achieved with clopidogrel in the CAPRIE
study among 19,185 patients with vascular disease was
identical to that achieved with ticlopidine in three random-
ized trials that included 3,471 vascular disease patients,
suggesting that clopidogrel and ticlopidine have similar
efficacy (8,17,18).
However, there are reasons to believe that clopidogrel
might be more effective than ticlopidine in stent patients.
Loading doses of clopidogrel up to 375 mg are well
tolerated and speed the onset of platelet inhibition (9). One
hour after a 375-mg loading dose, platelet response to ADP
was inhibited by 55% in healthy volunteers, far more rapid
inhibition than can achieved with ticlopidine (6,9). Clopi-
dogrel does not cause neutropenia or thrombotic thrombo-
cytopenic purpura, has fewer minor side effects, and is 25%
to 30% less expensive (6,8).
In the current study, one patient in whom clopidogrel had
been discontinued suffered stent thrombosis. The 95%
confidence intervals for one case in 500 patients are 0.01%
to 1.1%, and 0–0.74% if only patients who were taking
clopidogrel are analyzed (0 events in 500 patients). Larger
randomized studies are needed to determine whether stent
thrombosis is significantly less frequent with clopidogrel
than with ticlopidine.
Unanswered questions. Stent thrombosis occurring .14
days after stent deployment is very rare in patients treated
with aspirin and a thienopyridine (11,15). It is unclear
whether clopidogrel need be discontinued after two weeks,
since, unlike ticlopidine, clopidogrel does not cause hema-
tologic abnormalities with longer treatment duration. How-
ever, in 1,327 patients treated with dual antiplatelet therapy
Figure 1. Adverse events within 30 days.
Table 2. Angiographic and Procedural Characteristics
Ticlopidine
(N 5 827)
Clopidogrel
(N 5 500)
p
Value
Segments treated 1,061 703 NA
Stents used (%) 0.001
Palmaz-Schatz coronary 78 1
Gianturco-Roubin 19 0
Multilink 0 34
AVE 0 35
Others 3 20
Stents deployed 1,252 836 NA
Stents placed/patient (%) 0.02
1 64 57
2 25 27
3 8 9
$4 3.4 6.4
Stents/patient (mean) 1.5 1.7 0.002
AHA/ACC lesion type (%) 0.04
A 3 1
B1 19 15
B2 39 38
C 40 47
Maximal inflation (atm) 17 6 4 15 6 4 0.001
Nominal stent size, mm 3.3 6 0.5 3.3 6 0.4 0.99
Abciximab (%) 38 37 0.34
Low molecular weight heparin
(%)
11 3.2 0.001
NA 5 not applicable; AVE 5 arterial vascular engineering (Micro Stent II and
GFX).
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in this study, stent thrombosis did not occur during the
second two weeks. The optimal loading dose of clopidogrel
is also unknown.
Study limitations. The stent designs placed were different
in the two groups. However, stent thrombosis rates were
similar in the stent equivalency trials comparing the
Palmaz-Schatz stent, which was the most frequently used
stent in the ticlopidine patients, with the newer stents used
in the clopidogrel patients.
Because of the small number of events, the study lacked
sufficient statistical power to determine with certainty
whether clinically significant differences existed between the
two treatment arms. In a study of this size, if the true 30-day
event rate with ticlopidine was 1.6% (as observed in this
study), the statistical power would be 43% to detect an event
rate with clopidogrel of 0.5% with a p value of 0.05. The study
had 75% power to detect an event rate with clopidogrel of 4.0%
with a p value of 0.05. Hence, the results of this study
suggesting equivalency should be viewed with caution, and
should be considered in context with other studies suggesting
equivalency rather than as a definitive study on its own.
Conclusions. The results of this study suggest that clopi-
dogrel is at least as effective as ticlopidine at preventing stent
thrombosis and other adverse events within 30 days in
patients undergoing coronary stent implantation (19).
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